Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sernova Corp
T.SVA
Alternate Symbol(s):
SEOVF
Healthcare
Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a...
novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:SVA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 12, 2022 9:27am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Suspicious
My point was that the article you posted before had nothing to do with sernova. They were talking about portal vein injection. You know, the same injection that is rendering sernova patients insulin
...more
(239)
•••
Charly50
X
View Profile
View Bullboard History
Comment by
Charly50
on May 12, 2022 8:45am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Suspicious
and the carrot continues to dangle.... there is no connection?? I have another opinion. I) Islet Transplant Into Man Using Sernova's Cell Pouch(TM) for ...https://finance.yahoo.com › news
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 11, 2022 8:38pm
RE:RE:RE:RE:RE:RE:RE:RE:Suspicious
Keep your bratwurst in your pants chuck. This article is about the Edmonton protocol and nothing to do with sernova.
(239)
•••
Charly50
X
View Profile
View Bullboard History
Comment by
Charly50
on May 11, 2022 5:50pm
RE:RE:RE:RE:RE:RE:RE:Suspicious
Piotr Witkowski rospom1a4Mu3uig01: fi. 083 · Remember Liz?
...more
(239)
•••
Charly50
X
View Profile
View Bullboard History
Comment by
Charly50
on May 11, 2022 5:13pm
RE:RE:RE:RE:RE:RE:RE:Suspicious
thanks for this question. I have no doubts that Piotr will be present. HE WILL NOT PASS THIS OPPORTUNITY. There is also a lot at stake for him personally. He seems very determined. Check out his
...more
(5)
•••
Mercuryfilling1
X
View Profile
View Bullboard History
Comment by
Mercuryfilling1
on May 11, 2022 10:30am
RE:RE:RE:RE:RE:RE:Suspicious
Charly: As the principal investigator, P. Witkowski's presence at the podium would be nice - but it's not a sure thing. He's a busy guy. Any one of his twelve co-authors might be
...more
(239)
•••
Charly50
X
View Profile
View Bullboard History
Comment by
Charly50
on May 11, 2022 4:50am
RE:RE:RE:RE:RE:Suspicious
...and also the target price of 2.50 (Douglas Loe from Leede Jones Gable) grabbed the toilet. Nonetheless, I am looking to the future. We agree that P. Witkowski's presence at the event mentioned
...more
(43)
•••
Metalsguy1
X
View Profile
View Bullboard History
Comment by
Metalsguy1
on May 10, 2022 7:41pm
RE:RE:RE:RE:Suspicious
Let's not forget we had a $1 price target for years. Then when we blew right past that target the analyst made sure the price got beat right back down.
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 09, 2022 10:37pm
RE:RE:RE:Suspicious
They have done foolish things before. You think a company will give them rights to or a cell line for nothing? Vertex bought Semma cells for 1 billion. The way the share price is being held is very
...more
(43)
•••
Metalsguy1
X
View Profile
View Bullboard History
Comment by
Metalsguy1
on May 09, 2022 10:35pm
RE:RE:RE:Suspicious
Foolish is Spillups middle name.
(73)
•••
Sailboatdream
X
View Profile
View Bullboard History
Comment by
Sailboatdream
on May 09, 2022 10:13pm
RE:RE:Suspicious
With share price targets of $3 by year end (which is in 7 months). Dilution at $1.40 would be absolutely foolish!
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 09, 2022 6:00pm
RE:Suspicious
So no one else here finds it unusual that the share price is obviously being held in a range? No concerns that this long awaited deal might dilute our shares? Injection of pharma capital in exchange
...more
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 09, 2022 2:24pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Metalle,when are you going to make another post with content
Trying to accumulate on thin volume is tough without increasing the price ;)
(239)
•••
Charly50
X
View Profile
View Bullboard History
Post by
Charly50
on May 09, 2022 2:18pm
Press Release - May 09, 2022
Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022 LONDON, ONTARIO – May 9, 2022
...more
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >